查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1844307

胃腸道間質瘤治療市場機會、成長動力、產業趨勢分析及2025-2034年預測

Gastrointestinal Stromal Tumor Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球胃腸道間質瘤治療市場價值為 15 億美元，預計到 2034 年將以 8.3% 的複合年成長率成長至 32 億美元。

胃腸道間質瘤治療市場 - IMG1

這一成長可歸因於全球胃腸道癌症盛行率的上升以及人們對罕見腫瘤類型認知的提高。標靶治療，尤其是酪胺酸激酶抑制劑 (TKI) 的進展，正在顯著改善治療效果和存活率。轉移性和難治性胃腸道間質瘤 (GIST) 病例的發病率不斷上升，進一步刺激了對瑞普替尼、阿伐普替尼和瑞戈非尼等創新藥物的需求，這些藥物用於控制病情進展並改善患者在各個疾病階段的生活品質。 GIST 的治療通常為口服給藥，可透過醫院藥局、零售藥局和線上平台取得。這些療法包括酪胺酸激酶抑制劑、多激酶抑制劑和聯合療法等類別，都是針對原發性腫瘤和轉移性腫瘤。眾多全球製藥公司佔據市場，它們持續大力投資研發，從而推動了新療法的批准和治療適應症的擴展。精準腫瘤學和突變特異性治療的引入正在重塑市場，針對特定基因突變量身定做的藥物表現出更高的療效和更少的副作用。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 15億美元
預測值 32億美元
複合年成長率 8.3%

2024年，酪胺酸激酶抑制劑在胃腸道間質瘤（GIST）治療市場中佔62.3%的佔有率，這得益於其標靶作用和經過驗證的臨床療效。隨著個人化醫療的日益普及，酪胺酸激酶抑制劑的需求激增。美國國立衛生研究院 (NIH) 的研究指出，這些藥物，尤其是伊馬替尼，被認為是轉移性GIST的標準一線治療藥物，並因其高效性而持續受到青睞。

到2034年，品牌藥物市場的複合年成長率將達到8.1%。品牌療法因其臨床成功、FDA批准以及全球治療指南的持續收錄而備受青睞。這些療法針對的是KIT和PDGFRA等胃腸道間質瘤（GIST）患者常見的特定基因突變。持續的研發投入正在推動下一代酪胺酸激酶抑制劑（TKI）和聯合療法的研發，旨在克服抗藥性並改善治療效果。

2024年，美國胃腸道間質瘤治療市場規模達5.618億美元，市場需求龐大。隨著影像診斷和分子檢測技術的進步，美國越來越多的胃腸道間質瘤病例被準確診斷，尋求治療的患者數量也隨之增加。此外，FDA的扶持性法規和報銷政策也促進了品牌藥和學名藥的核准和應用，進一步拓展了市場機會。

胃腸道間質瘤治療市場的主要參與者包括拜耳、輝瑞、武田製藥、羅氏、諾華、太陽製藥、Shorla Oncology、Glenmark、AngioDynamics、Argon Medical Products、Natco Pharma 和 Deciphera Pharma。為了鞏固其在胃腸道間質瘤治療市場中的地位，各公司正專注於幾個關鍵策略。這包括大力投資研發 (R&D)，將創新療法推向市場並擴展現有產品線。許多公司正在優先開發下一代酪胺酸激酶抑制劑和聯合療法，特別是那些針對抗藥性機制的療法。此外，公司正在透過與研究機構和其他製藥公司建立策略合作夥伴關係來加速藥物開發和拓寬分銷網路，從而加強其市場立足點。透過長期臨床試驗資料、FDA 批准和融入全球治療指南來增強品牌權益也是一個關鍵的重點。最後，各公司正在擴大其地理覆蓋範圍，增加新興市場的治療機會，而這些市場的胃腸道間質瘤發病率正在上升，從而最大限度地發揮成長潛力。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
    • 供應商格局
    • 每個階段的增值
    • 影響價值鏈的因素
  • 產業衝擊力
    • 成長動力
      • 胃腸道間質瘤盛行率不斷上升
      • 年齡增加和遺傳傾向
      • 標靶治療的突破
      • 對復發和抗藥性的認知不斷提高
    • 產業陷阱與挑戰
      • 不良反應和治療抵抗
      • 低收入地區的交通受限
    • 市場機會
      • 突變特異性和聯合療法的開發
      • 基因組檢測與個人化醫療的擴展
  • 成長潛力分析
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 未來市場趨勢
  • 技術格局
    • 現有技術
    • 新興技術
  • 管道分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與協作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按藥物類型，2021 - 2034 年

  • 主要趨勢
  • 多激酶抑制劑
  • 酪胺酸激酶抑制劑
  • VEGF抑制劑

第6章：市場估計與預測：按類型，2021 - 2034

  • 主要趨勢
  • 品牌
  • 泛型

第7章：市場估計與預測：按年齡層，2021 - 2034 年

  • 主要趨勢
  • 成年人
  • 老年

第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：市場估計與預測：按地區，2021 - 2034

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Bayer
  • Deciphera Pharmaceuticals
  • F. Hoffmann-La Roche
  • Glenmark
  • Natco Pharma
  • Novartis
  • Pfizer
  • Sanofi
  • Shorla Oncology
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
簡介目錄
Product Code: 14797

The Global Gastrointestinal Stromal Tumor Treatment Market was valued at USD 1.5 billion in 2024 and is estimated to grow at a CAGR of 8.3% to reach USD 3.2 billion by 2034.

Gastrointestinal Stromal Tumor Treatment Market - IMG1

This growth can be attributed to the increasing global prevalence of gastrointestinal cancers and heightened awareness of rare tumor types. Advancements in targeted therapies, particularly tyrosine kinase inhibitors (TKIs), are improving treatment outcomes and survival rates significantly. The rising incidence of metastatic and treatment-resistant GIST cases has further fueled demand for innovative drugs like ripretinib, avapritinib, and regorafenib, which are used to manage disease progression and enhance patient quality of life at various stages of the condition. Treatments for GIST are typically administered orally and are available through hospital pharmacies, retail pharmacies, and online platforms. These therapies include categories such as tyrosine kinase inhibitors, multikinase inhibitors, and combination treatments, all aimed at both primary and metastatic tumors. The market is populated by numerous global pharmaceutical companies that continue to invest heavily in research and development, resulting in the approval of new therapies and expanded treatment indications. The introduction of precision oncology and mutation-specific treatments is reshaping the market, with drugs tailored to specific genetic mutations demonstrating higher efficacy and fewer side effects.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.5 Billion
Forecast Value$3.2 Billion
CAGR8.3%

In 2024, the tyrosine kinase inhibitors segment held a share of 62.3% in the GIST treatment market, driven by their targeted action and proven clinical effectiveness. As personalized medicine becomes more prevalent, the demand for tyrosine kinase inhibitors has surged. These drugs, particularly imatinib, are considered the standard first-line treatment for metastatic GIST and continue to be preferred due to their high efficacy, as noted by research from the National Institutes of Health (NIH).

The branded drug segment will grow at a CAGR of 8.1% through 2034. Branded therapies are favored due to their demonstrated clinical success, FDA approvals, and consistent inclusion in global treatment guidelines. These treatments target specific genetic mutations like KIT and PDGFRA, which are commonly found in GIST patients. Ongoing investments in research and development are driving the creation of next-generation tyrosine kinase inhibitors (TKIs) and combination therapies designed to overcome drug resistance and improve treatment outcomes.

United States Gastrointestinal Stromal Tumor Treatment Market was valued at USD 561.8 million in 2024, reflecting significant demand. With the advancement of diagnostic imaging and molecular testing, more GIST cases are being accurately detected in the U.S., leading to an increased number of patients seeking treatment. Additionally, supportive FDA regulations and reimbursement policies are facilitating the approval and adoption of both branded and generic treatments, further expanding market opportunities.

Major players in the Gastrointestinal Stromal Tumor Treatment Market include Bayer, Pfizer, Takeda Pharmaceuticals, F. Hoffmann-La Roche, Novartis, Sun Pharma, Shorla Oncology, Glenmark, AngioDynamics, Argon Medical Products, Natco Pharma, and Deciphera Pharma. To strengthen their position in the gastrointestinal stromal tumor treatment market, companies are focusing on several key strategies. This includes heavy investment in research and development (R&D) to bring innovative treatments to market and expand existing product lines. Many companies are prioritizing the development of next-generation tyrosine kinase inhibitors and combination therapies, particularly those targeting resistance mechanisms. Additionally, companies are enhancing their market foothold by forming strategic partnerships with research institutions and other pharmaceutical companies to accelerate drug development and broaden distribution networks. Strengthening brand equity through long-term clinical trial data, FDA approvals, and integration into global treatment guidelines is also a critical focus. Finally, companies are expanding their geographical reach and increasing access to treatments in emerging markets, where the incidence of GIST is rising, thereby maximizing growth potential.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumption and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Drug type trends
    • 2.2.3 Type trends
    • 2.2.4 Age group trends
    • 2.2.5 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier landscape
    • 3.1.2 Value addition at each stage
    • 3.1.3 Factor affecting the value chain
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence gastrointestinal stromal tumors
      • 3.2.1.2 Advancing age and genetic predisposition
      • 3.2.1.3 Breakthroughs in targeted therapy
      • 3.2.1.4 Growing awareness of recurrence and resistance
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Adverse effects and resistance to therapy
      • 3.2.2.2 Limited access in low-income regions
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of mutation-specific and combination therapies
      • 3.2.3.2 Expansion of genomic testing and personalized medicine
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Future market trends
  • 3.6 Technological landscape
    • 3.6.1 Current technologies
    • 3.6.2 Emerging technologies
  • 3.7 Pipeline analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Multikinase inhibitors
  • 5.3 Tyrosine kinase inhibitors
  • 5.4 VEGF inhibitors

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Branded
  • 6.3 Generics

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adults
  • 7.3 Geriatric

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Bayer
  • 10.2 Deciphera Pharmaceuticals
  • 10.3 F. Hoffmann-La Roche
  • 10.4 Glenmark
  • 10.5 Natco Pharma
  • 10.6 Novartis
  • 10.7 Pfizer
  • 10.8 Sanofi
  • 10.9 Shorla Oncology
  • 10.10 Sun Pharmaceuticals
  • 10.11 Takeda Pharmaceuticals